NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
15.41
-0.61 (-3.81%)
Nov 16, 2026, 4:00 PM EST - Market closed
NeoGenomics Revenue
NeoGenomics had revenue of $209.25M in the quarter ending September 30, 2026, with 11.43% growth. This brings the company's total for the last twelve months to $787.75M, up 11.08% year-over-year. In the year 2025, NeoGenomics had annual revenue of $727.33M with 10.11% growth. That makes NeoGenomics the 8,799th largest company in the world by revenue and 1,970th in the United States.
Revenue (ttm)
$787.75M
Revenue Growth
+11.08%
P/S Ratio
2.53
Revenue / Employee
$315,101
Employees
2,500
Market Cap
1.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 727.33M | 66.77M | 10.11% |
| Dec 31, 2024 | 660.57M | 68.92M | 11.65% |
| Dec 31, 2023 | 591.64M | 81.92M | 16.07% |
| Dec 31, 2022 | 509.73M | 25.40M | 5.24% |
| Dec 31, 2021 | 484.33M | 39.88M | 8.97% |
| Dec 31, 2020 | 444.45M | 35.62M | 8.71% |
| Dec 31, 2019 | 408.83M | 132.09M | 47.73% |
| Dec 31, 2018 | 276.74M | 36.49M | 15.19% |
| Dec 31, 2017 | 240.25M | 8.44M | 3.64% |
| Dec 31, 2016 | 231.81M | 132.01M | 132.27% |
| Dec 31, 2015 | 99.80M | 12.73M | 14.62% |
| Dec 31, 2014 | 87.07M | 20.60M | 31.00% |
| Dec 31, 2013 | 66.47M | 6.60M | 11.02% |
| Dec 31, 2012 | 59.87M | 16.38M | 37.68% |
| Dec 31, 2011 | 43.48M | 9.11M | 26.51% |
| Dec 31, 2010 | 34.37M | 4.90M | 16.63% |
| Dec 31, 2009 | 29.47M | 9.45M | 47.23% |
| Dec 31, 2008 | 20.02M | 8.51M | 73.97% |
| Dec 31, 2007 | 11.50M | 5.03M | 77.65% |
| Dec 31, 2006 | 6.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sotera Health Company | 1.23B |
| OPKO Health | 654.10M |
| Veracyte | 581.78M |
| CareDx | 497.40M |
| GeneDx Holdings | 460.78M |
| BillionToOne | 436.87M |
| Castle Biosciences | 377.13M |
| Adaptive Biotechnologies | 298.01M |
NEO News
- 10 days ago - NeoGenomics to Participate in Upcoming Investor Conferences - Business Wire
- 18 days ago - NeoGenomics price target raised to $23 from $19 at TD Cowen - TheFly
- 18 days ago - NeoGenomics price target raised to $21 from $16.50 at Jefferies - TheFly
- 19 days ago - NeoGenomics reports Q3 adjusted EPS 7c, consensus 6c - TheFly
- 19 days ago - NeoGenomics raises FY26 revenue view to $807M-$809M from $802M-$806M - TheFly
- 19 days ago - NeoGenomics Earnings Call Transcript: Q3 2026 - Transcripts
- 19 days ago - NeoGenomics Earnings release: Q3 2026 - Filings
- 19 days ago - NeoGenomics Slides: Q3 2026 - Filings